We are a CRDMO company founded in 2020 focusing on viral vector and nucleic acid drugs. We have state-of-the-art technology empowered by strong R&D capability and large-scale commercial production facilities in China and North America. The Shanghai facility is over 70000m2 and has been opened to customers while the remaining is under accelerated construction.
Our one-stop service platform of viral vector and nucleic acid drugs to help customers from drug discovery, proof-of-concept study, preclinical study, to CMC development, commercialization, and regulatory filing including IND and BLA.
Your technique, your know-hows, your protocols and your IP will be protected under our customer IP privacy protection procedures.